ArticleNature communications2023
Metabolomic differentiation of benign vs malignant pulmonary nodules with high specificity via high-resolution mass spectrometry analysis of patient sera.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Risk prediction for lung cancer screening: a systematic review and meta-regression.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Circulating proteins associated with histological subtypes of lung cancer from genetic and population-based perspectives.PLoS genetics · 2025Pooled it
- Targeted detection of amino acid profiles in pleural fluid and serum by liquid chromatography-tandem mass spectrometry for estimating the risks of four aetiologies of pleural effusion: a proof-of-concept study.Annals of medicine · 2026Article
- Positive feedback loop via HIF-1α lactylation driven by kynurenine promotes glycolysis.Oncogene · 2026Article
- A high-resolution circulating metabolic atlas of lung adenocarcinoma progression supports early and accurate diagnosis.Cell reports. Medicine · 2026Article
- Microbiome-host interactions in different pathomic subtypes of early-stage lung adenocarcinoma.BMC pulmonary medicine · 2026Article
- A Reporting Guideline for Observational Studies in Metabolomic Epidemiology: Explanation and Elaboration of the Strobe-MetEpi Checklist.Research square · 2026Article
- Differential diagnosis of benign and malignant pulmonary nodules attached to the interlobar pleura.Quantitative imaging in medicine and surgery · 2026Article
- [Glycolytic Reprogramming in Lung Adenocarcinoma: Molecular Mechanisms, Metabolic Biomarkers and Targeted Therapeutic Strategies].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Improving risk stratification of pulmonary nodules: an integrated perinodular vascular and radiomic model for clinical decision support.BMC medical imaging · 2026Article
- Ensemble learning on serum metabolic fingerprints for early detection of lung adenocarcinoma.NPJ precision oncology · 2026Article
- CsdA-LaeB Regulatory Hub Contributes to Aspergillus fumigatus Virulence via Fumiquinazoline C Biosynthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of High-Performing Blood Metabolite Biomarkers of Lung Cancer in a Chinese Population.Phenomics (Cham, Switzerland) · 2026Article
- Enhanced early detection of thyroid cancer using ensemble machine learning and serum proteomics.Frontiers in oncology · 2026Article
- Biomarker discovery for lung adenocarcinoma diagnosis using liquid chromatography-mass spectrometry-based enhanced pseudotargeted metabolomics.Analytical and bioanalytical chemistry · 2026Article
- Plasma metabolic landscape unveils key regulators of leukemia subtype progression.Future science OA · 2025Article
- Development and multi-center validation of machine learning models based on targeted metabolomics for rheumatoid arthritis.Journal of translational medicine · 2025Article
- Serum from patients with oral squamous cell carcinoma remodels the tumor immune escape ecological niche by promoting regulatory T‑cell differentiation and T‑cell exhaustion.Oncology reports · 2025Article
- Lipidomic profiling of human bile distinguishes cholangiocarcinoma from benign bile duct diseases with high specificity and sensitivity: a prospective descriptive study.British journal of cancer · 2025Article
- Biomarkers via liquid biopsy for distinguishing malignant from benign pulmonary ground-glass nodule.iScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differential diagnosis of pulmonary nodules detected by computed tomography (CT) remains a challenge in clinical practice. Here, we characterize the global metabolomes of 480 serum samples including healthy controls, benign pulmonary nodules, and stage I lung adenocarcinoma. The adenocarcinoma demonstrates a distinct metabolomic signature, whereas benign nodules and healthy controls share major similarities in metabolomic profiles. A panel of 27 metabolites is identified in the discovery cohort (n = 306) to distinguish between benign and malignant nodules. The discriminant model achieves an AUC of 0.915 and 0.945 in the internal validation (n = 104) and external validation cohort (n = 111), respectively. Pathway analysis reveals elevation in glycolytic metabolites associated with decreased tryptophan in serum of lung adenocarcinoma vs benign nodules and healthy controls, and demonstrates that uptake of tryptophan promotes glycolysis in lung cancer cells. Our study highlights the value of the serum metabolite biomarkers in risk assessment of pulmonary nodules detected by CT screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.